Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Impedimed Limited ( (AU:IPD) ) has issued an update.
ImpediMed director Christine Emmanuel-Donnelly has increased her indirect stake in the company through an on-market purchase executed via the Donnelly Superannuation Fund. The fund acquired 1.5 million ImpediMed ordinary shares at $0.019573 per share, lifting its holding to 3,236,255 shares, while her direct and other indirect holdings through IDEAHL Pty Ltd remain unchanged, modestly strengthening insider ownership in the stock.
The transaction signals continued financial commitment from a board member and may be interpreted by investors as a sign of confidence in ImpediMed’s outlook and valuation. With no shares disposed and all changes limited to an on-market trade, the move marginally consolidates Emmanuel-Donnelly’s overall economic interest in the company without altering its broader capital structure.
The most recent analyst rating on (AU:IPD) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian-listed medical technology company that develops and commercialises bioimpedance-based devices and related solutions for clinical use. Its products focus on measuring and managing fluid status in patients, targeting applications such as lymphedema and heart failure management in healthcare markets.
YTD Price Performance: -44.12%
Average Trading Volume: 3,940,090
Technical Sentiment Signal: Sell
Current Market Cap: A$38.74M
Learn more about IPD stock on TipRanks’ Stock Analysis page.